Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Theraclion performs its first two non-invasive treatments of benign breast tumors in United States


Tuesday, 20 May 2014 01:33pm EDT 

Theraclion SA:Announces realization of first treatments of breast fibroadenoma with Echopulse device in United States.Last February United States Food and Drug Administration granted company IDE (Investigational Device Exemption), allowing it to conduct this clinical trial, which is the first step toward obtaining PMA (Premarket approval) in United States.Study aims to collect data on safety and efficacy of Echopulse for indication of breast fibroadenoma.